Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.58 |
| ▸ | MAPT | P10636 | 7/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 6/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21628158 | 0.90 | PI4KB (0.59) | PI4KBALDH1A1MAPTKDM4ENPSR1 | |
| SCHEMBL21628162 | 0.90 | PI4KB (0.73) | PI4KBALDH1A1MAPTKDM4ENPSR1 | |
| SCHEMBL20528890 | 0.89 | PI4KB (0.60) | PI4KBALDH1A1MAPTKDM4ENPSR1 | |
| SCHEMBL29644477 | 0.89 | PI4KB (0.60) | PI4KBALDH1A1MAPTKDM4ENPSR1 | |
| SCHEMBL29644495 | 0.89 | PI4KB (0.57) | PI4KBALDH1A1MAPTKDM4ENPSR1 | |
| SCHEMBL20529103 | 0.89 | PI4KB (0.57) | PI4KBALDH1A1MAPTKDM4ENPSR1 | |
| SCHEMBL23387092 | 0.88 | PI4KB (0.56) | PI4KBALDH1A1MAPTKDM4ENPSR1 | |
| SCHEMBL29644425 | 0.88 | PI4KB (0.55) | PI4KBALDH1A1MAPTKDM4ENPSR1 | |
| SCHEMBL20529179 | 0.88 | PI4KB (0.55) | PI4KBALDH1A1MAPTKDM4ENPSR1 | |
| SCHEMBL20528876 | 0.87 | PI4KB (0.57) | PI4KBALDH1A1MAPTKDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676485-A1 | COMPOUND AND FORMULATION FOR SYSTEMIC THERAPY BY ORAL TRANSMUCOSAL ADMINISTRATION | CUROVIR AB (SE) | 2026-01-14 | — | — | EP | claimed |
| WO-2024184442-A1 | COMPOUND AND FORMULATION FOR SYSTEMIC THERAPY BY ORAL TRANSMUCOSAL ADMINISTRATION | CUROVIR AB (SE) | 2024-09-12 | — | — | WO | claimed |
| EP-4028131-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2023-11-22 | — | — | EP | claimed |
| EP-3606926-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2021-05-26 | — | — | EP | claimed |
| US-20200031833-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2020-01-30 | — | — | US | claimed |
| EP-4676485-A1 | COMPOUND AND FORMULATION FOR SYSTEMIC THERAPY BY ORAL TRANSMUCOSAL ADMINISTRATION | CUROVIR AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024184442-A1 | COMPOUND AND FORMULATION FOR SYSTEMIC THERAPY BY ORAL TRANSMUCOSAL ADMINISTRATION | CUROVIR AB (SE) | 2024-09-12 | — | — | WO | disclosed |
| EP-4028131-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2023-11-22 | — | — | EP | disclosed |
| EP-4028131-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2023-11-22 | — | — | EP | disclosed |
| EP-3606926-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2021-05-26 | — | — | EP | disclosed |
| EP-3606926-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2021-05-26 | — | — | EP | disclosed |
| US-11001587-B2 | Substituted indazoles as phosphatidylinositol kinase inhibitors | CUROVIR AB (SE) | 2021-05-11 | — | — | US | disclosed |
| US-11001587-B2 | Substituted indazoles as phosphatidylinositol kinase inhibitors | CUROVIR AB (SE) | 2021-05-11 | — | — | US | disclosed |
| WO-2021032611-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2021-02-25 | — | — | WO | disclosed |
| US-20200031833-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2020-01-30 | — | — | US | disclosed |
| US-20200031833-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001587-B2 | Substituted indazoles as phosphatidylinositol kinase inhibitors | PIKFYVE, PI4KA, PIP4K2B | PI4KB 6/4885ALDH1A1 4239/4885MAPT 503/4885 |
| US-20200031833-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | BECN1, SQSTM1, TFEB | PI4KB 630/4885ALDH1A1 1445/4885MAPT 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.